



Original Article

Frequency and Prognostic Value of KRAS, NRAS, and BRAF Mutations in Metastatic Colorectal Cancer: An Iranian Cohort Study

Abbas Eshraghi¹, Mohammad Sadegh Ghasemi², Jamshid Vafaeimanesh³, Mohammad Sina Mirjani⁴, Mostafa Vahedian⁵, Mohammad Reza Ahmadi⁴

¹Department of Internal Medicine, Hematology & Oncology, School of Medicine, Qom University of Medical Sciences, Qom, Iran

²Clinical Research of Development Center, Shahid Beheshti Hospital, Qom University of Medical Sciences, Qom, Iran

³Department of Internal Medicine, School of Medicine, Qom University of Medical Sciences, Qom, Iran

⁴Student Research Committee, Faculty of Medicine, Qom University of Medical Sciences, Qom, Iran

⁵Research Center for Environmental Pollutants, Qom University of Medical Sciences, Qom, Iran

Abstract

Introduction: Colorectal cancer (CRC) is characterized by genetic mutations, particularly in the Rat sarcoma (RAS) and V-Raf Murine Sarcoma Viral Oncogene Homolog B (BRAF) oncogenes, which affect the prognosis and response to treatment. This study investigated the rates of Kirsten Rat Sarcoma Viral oncogene homolog (K-RAS), neuroblastoma RAS viral oncogene homolog (N-RAS), and BRAF mutations and their association with 1-year survival among patients with metastatic CRC.

Methods: This retrospective study included 83 patients with metastatic CRC from the oncology clinic at Shahid Beheshti Hospital, Qom, Iran. Demographic and clinical data, including mutation status, were collected. One-year patient survival was assessed.

Results: In total, mutation frequencies were 47% for K-RAS, 14.5% for N-RAS, and 6% for BRAF. BRAF mutations were significantly more frequent in patients under 50 years of age, while KRAS and NRAS mutations showed no significant associations with age, sex, tumor site, or metastatic pattern. No significant association was observed between 1-year survival and KRAS, NRAS, or BRAF mutation status.

Conclusion: BRAF mutations were significantly associated with an age of diagnosis under 50 years; however, neither BRAF, KRAS, nor NRAS mutations demonstrated a significant association with other clinicopathological characteristics or 1-year survival in this cohort.

Keywords: Metastatic colorectal cancer, KRAS mutation, NRAS mutation, BRAF mutation

Cite this article as: Eshraghi A, Ghasemi MS, Vafaeimanesh J, Mirjani MS, Vahedian M, Ahmadi MR. Frequency and prognostic value of KRAS, NRAS, and BRAF mutations in metastatic colorectal cancer: an Iranian cohort study. Middle East J Dig Dis 2026;18(2): 93-99. doi:10.34172/mejdd.3400

Received: January 17, 2026, **Revised:** March 9, 2026, **Accepted:** March 10, 2026, **ePublished:** April 30, 2026

Introduction

Colorectal cancer (CRC) is the third most prevalent malignancy worldwide, with an annual increase of 10.2% in the number of new cases.¹ Despite advancements in screening programs, approximately 20-25% of patients with CRC still present with metastatic disease at the time of diagnosis.² The 5-year survival rate for patients with non-metastatic CRC is estimated to be around 91%, whereas it dramatically declines to approximately 15% for those diagnosed with metastatic disease.³ Despite the significant progress in managing metastatic colorectal cancer (mCRC), recent years have shown no improvement in the median overall survival of these patients.⁴

These findings underscore the need to elucidate the molecular and genetic profiles of mCRC to optimize therapeutic strategies.⁵ In CRC, the roles of mutated genes in the production of cancerous cells and in tumorigenesis are of significant importance.

Mutations involving proto-oncogenes and their subsequent transformation into oncogenes are among the most critical pathophysiological alterations in these malignancies.⁶ Among these proto-oncogenes, mutations in the rat sarcoma (RAS) proto-oncogenes, including Kirsten rat sarcoma viral oncogene homolog (KRAS) and neuroblastoma rat sarcoma viral oncogene homolog (NRAS), are among the most often observed mutations in different malignancies, including colon adenocarcinoma, pancreatic cancer, lung cancer, and hematologic malignancies.⁷ Furthermore, the V-Raf Murine Sarcoma Viral Oncogene Homolog B (BRAF) mutation is associated with a poor prognosis and occurs in approximately 5% to 11% of patients with mCRC.⁸

Several international studies have examined the clinical impact and frequency of these proto-oncogenes. However, there is limited evidence on this proto-oncogene in the Middle Eastern population, particularly in Iran.⁹ In this



*Corresponding Author: Abbas Eshraghi, Email: ae845@yahoo.com



© 2026 The Author(s). This work is published by Middle East Journal of Digestive Diseases as an open access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

study, we examined the association between patient prognosis and mortality in patients with mCRC, as the identification of mutations in the NRAS, KRAS, and BRAF oncogenes is crucial for determining treatment response and prognosis.^{10, 11} The purpose of this study was to determine the frequency of genetic variants in the K-RAS, N-RAS, and BRAF oncogenes, and the 1-year survival rate for each oncogene, in patients with mCRC.

Materials and Methods

Study Design

This retrospective cohort study included 83 patients diagnosed with mCRC at the oncology clinic of Shahid Beheshti Hospital, Qom, between 2019 and 2023. The diagnosis was confirmed by histological biopsy and imaging. Eligible patients underwent molecular testing for KRAS, NRAS, and BRAF mutations. Patients were monitored for 1 year following diagnosis to assess disease progression and survival through clinical visits and telephone follow-ups.

Medical records provided patient demographic and clinical data, including age, sex, tumor site, histological features, and metastasis status. The inclusion criteria were a diagnosis of mCRC, referral to the oncology clinic at Shahid Beheshti Hospital in Qom between 2019 and 2023, and a history of chemotherapy. Researchers excluded patients who did not provide consent to participate, did not complete follow-up, or had incomplete data available.

Mutation Assessment

After patient selection, tumor samples were analyzed as either fresh-frozen tissues or formalin-fixed, paraffin-embedded (FFPE) blocks containing at least 50% tumor cells. 4–5 sections with a thickness of 2–5 μm were prepared, and DNA was extracted using the QIAamp DNA FFPE Tissue Kit (Qiagen). For FFPE-derived DNA, a pre-amplification step was performed before high-resolution melting (HRM) analysis.

Polymerase chain reaction (PCR) amplification was carried out under the following conditions: an initial denaturation at 95 °C for 11 minutes, followed by 30 cycles of denaturation at 95 °C for 30 seconds, annealing at 55 °C for 30 seconds, and extension at 72 °C for 30 seconds, with a final extension at 72 °C for 5 minutes. Successful amplification was confirmed by electrophoresis, which showed a 120 bp fragment for KRAS and NRAS (primers K12&13F and 13mt-R) and a 147 bp fragment for BRAF exon 15.

The amplified fragments were analyzed using Gene Runner and MapViewer software to confirm the expected fragment length and restriction enzyme site (BglI) for restriction fragment length polymorphism (RFLP) analysis. Mutation status (wild-type or mutant) was determined by high-resolution melting (HRM) analysis. Samples with mutant profiles were further confirmed using allele-specific PCR, pyrosequencing, or direct DNA sequencing for BRAF V600E, KRAS, and NRAS mutations.

Statistical Analysis

Independent t-tests or ANOVA were performed for continuous variables to assess the association between mutation status and clinicopathological parameters. Conversely, categorical variables were analyzed using Chi-square or Fisher's exact tests as appropriate. Binary logistic regression analysis was used to identify independent predictors of mutation status. All statistical analyses were conducted in RStudio, and $P < 0.05$ was considered statistically significant.

Ethical Approval

This study was approved by the Research Ethics Committee of Qom University of Medical Sciences (Approval ID: IR.MUQ.REC.1401.207, Approval Date: January 8, 2023).

Results

During the research period, 83 patients met the inclusion criteria. The mean age of the patients was 54.87 ± 12.78 years. The patients' ages ranged from 23 to 85 years. A total of 30 female patients (35.4%) and 53 male patients (64.6%) were studied. The results indicated that mutations in the K-RAS gene (39 patients, 47%) were the most frequent among the oncogenes examined. Mutations in the N-RAS gene (12 patients, 14.5%) and BRAF gene (5 patients, 6%) were observed at lower frequencies.

Among patients with gene mutations, the lowest mean age was associated with BRAF mutations (40.2 years), and the highest with K-RAS mutations (57.59 years). A significant difference in mean age was observed between patients with mutated and wild-type BRAF genes ($P = 0.038$) (Table 1). However, findings regarding BRAF mutations should be interpreted with caution given the very small number of BRAF-mutant patients ($n = 5$).

The distribution of KRAS, NRAS, and BRAF mutations did not differ significantly by sex. KRAS mutations were present in 43.6% of females and 56.4% of males ($P = 0.184$). NRAS mutations occurred in 33.3% of females and 66.7% of males ($P = 1.000$). BRAF mutations were detected in 60% of females and 40% of males ($P = 0.346$). Overall, no significant association was observed between sex and mutation status for any of the three genes (Table 1).

The left colon was the predominant primary tumor site across KRAS (74.4%), NRAS (75%), and BRAF (60%) mutation groups, with no significant associations between primary tumor location and mutation status (KRAS: $P = 0.079$; NRAS: $P = 0.204$; BRAF: $P = 0.366$). The liver was the predominant site of metastasis across all mutation groups: KRAS (84.6%), NRAS (83.3%), and BRAF (80%). No significant association was found between mutation status and liver metastasis for KRAS ($P = 0.821$), NRAS ($P = 0.683$), or BRAF ($P = 0.552$) (Table 1).

One-year survival was evaluated in patients according to KRAS, NRAS, and BRAF mutation status. Overall, there were no statistically significant associations between KRAS ($P = 0.520$), NRAS ($P = 0.522$), or BRAF ($P = 0.346$) mutation status and 1-year survival (Table 1).

Among mutation-positive subgroups, none of the clinicopathological characteristics showed a significant association with 1-year survival (Table 2). Similarly, no clinicopathological factor was significantly associated with

1-year survival in wild-type gene subgroups (Table 3). In the overall population, only liver metastasis demonstrated a statistically significant association with 1-year survival ($P=0.048$) (Table 4).

Table 1. Baseline clinicopathological characteristics and one-year survival outcome

Characteristics		KRAS			NRAS			BRAF		
		Mutant (n=39)	Wild (n=44)	P	Mutant (n=12)	Wild (n=71)	P	Mutant (n=5)	Wild (n=78)	P
Primary tumor location	Left	29 (74.4%)	31 (70.5%)	0.079*	9 (75%)	51 (71.8%)	0.204*	3 (60%)	57 (73.1%)	0.366*
	Right	5 (12.8%)	12 (27.3%)		1 (8.3%)	16 (22.5%)		1 (20%)	16 (20.5%)	
	Unspecified	5 (12.8%)	1 (2.3%)		2 (16.7%)	4 (5.6%)		1 (20%)	5 (6.4%)	
Liver metastasis	No	6 (15.4%)	6 (13.6%)	0.821#	2 (16.7%)	10 (14.1%)	0.683*	1 (20%)	11 (14.1%)	0.552*
	Yes	33 (84.6%)	38 (86.4%)		10 (83.3%)	61 (85.9%)		4 (80%)	67 (85.9%)	
Lung metastasis	No	25 (64.1%)	36 (81.8%)	0.068#	8 (66.7%)	53 (74.6%)	0.724*	4 (80%)	57 (73.1%)	1*
	Yes	14 (35.9%)	8 (18.2%)		4 (33.3%)	18 (25.4%)		1 (20%)	21 (26.9%)	
Bone metastasis	No	38 (97.4%)	42 (95.5%)	1*	12 (100%)	68 (95.8%)	1*	5 (100%)	75 (96.2%)	1*
	Yes	1 (2.6%)	2 (4.5%)		0 (0%)	3 (4.2%)		0 (0%)	3 (3.8%)	
Lymph nodes metastasis	No	36 (92.3%)	41 (93.2%)	1*	11 (91.7%)	66 (93%)	1*	4 (80%)	73 (93.6%)	0.319*
	Yes	3 (7.7%)	3 (6.8%)		1 (8.3%)	5 (7%)		1 (20%)	5 (6.4%)	
Peritoneal metastasis	No	37 (94.9%)	36 (81.8%)	0.094*	10 (83.3%)	63 (88.7%)	0.633*	5 (100%)	68 (87.2%)	1*
	Yes	2 (5.1%)	8 (18.2%)		2 (16.7%)	8 (11.3%)		0 (0%)	10 (12.8%)	
Age	<50	9 (23.1%)	17 (38.6%)	0.127#	6 (50%)	20 (28.2%)	0.131#	4 (80%)	22 (28.2%)	0.032*
	≥50	30 (76.9%)	27 (61.4%)		6 (50%)	51 (71.8%)		1 (20%)	56 (71.8%)	
Sex	Male	22 (56.4%)	31 (70.5%)	0.184#	8 (66.7%)	45 (63.4%)	1*	2 (40%)	51 (65.4%)	0.346*
	Female	17 (43.6%)	13 (29.5%)		4 (33.3%)	26 (36.6%)		3 (60%)	27 (34.6%)	
One-year survival	Alive	23 (76.7%)	30 (68.2%)	0.520#	9 (75%)	44 (62%)	0.522*	2 (40%)	51 (65.4%)	0.346*
	Death	16 (23.3%)	14 (31.8%)		3 (25%)	27 (38.0%)		3 (60%)	27 (34.6%)	
Age (mean±SD)		57.59±12.49	52.45±12.69	0.067**	51.7±15.85	55.39±12.25	0.461**	40.20±11.71	55.81±12.33	0.038**

* = Fisher # = Chi-square ** = t-test.

Bold numbers indicate statistically significant p-values ($P < 0.05$).

Table 2. Association between clinicopathological characteristics and 1-year survival in mutant gene subgroups

Characteristics		KRAS-Mutant			NRAS-Mutant			BRAF-Mutant		
		Alive (n=23)	Death (n=16)	P	Alive (n=9)	Death (n=3)	P	Alive (n=2)	Death (n=3)	P
Primary tumor location	Left	15 (65.2%)	14 (87.5%)	0.158*	7 (77.8%)	2 (66.7%)	0.618*	1 (50%)	2 (66.7%)	1*
	Right	5 (21.7%)	0 (0%)		1 (11.1%)	0 (0%)		1 (50%)	0 (0%)	
	Unspecified	3 (13%)	2 (12.5%)		1 (11.1%)	1 (33.3%)		0 (0%)	1 (33.3%)	
Liver metastasis	No	6 (26.1%)	0 (0%)	0.064*	2 (22.2%)	0 (0%)	1*	1 (50%)	0 (0%)	0.400*
	Yes	17 (73.9%)	16 (100%)		7 (77.8%)	3 (100%)		1 (50%)	3 (100%)	
Lung metastasis	No	15 (65.2%)	10 (62.5%)	0.862#	5 (55.6%)	3 (100%)	0.491*	2 (100%)	2 (66.7%)	1*
	Yes	8 (34.8%)	6 (37.5%)		4 (44.4%)	0 (0%)		0 (0%)	1 (33.3%)	
Bone metastasis	No	23 (100%)	15 (93.8%)	0.410*	9 (100%)	3 (100%)	1*	2 (100%)	3 (100%)	1*
	Yes	0 (0%)	1 (6.2%)		0 (0%)	0 (0%)		0 (0%)	0 (0%)	
Lymph nodes metastasis	No	20 (87%)	16 (100%)	0.255*	8 (88.9%)	3 (100%)	1*	1 (50%)	3 (100%)	0.400*
	Yes	3 (13%)	0 (0%)		1 (11.1%)	0 (0%)		1 (50%)	0 (0%)	
Peritoneal metastasis	No	21 (91.3%)	16 (100%)	0.503*	7 (77.8%)	3 (100%)	1*	2 (100%)	3 (100%)	1*
	Yes	2 (8.7%)	0 (0%)		2 (22.2%)	0 (0%)		0 (0%)	0 (0%)	
Age	<50	6 (26.1%)	3 (18.8%)	0.711*	4 (44.4%)	2 (66.7%)	1*	1 (50%)	3 (100%)	0.400*
	≥50	17 (73.9%)	13 (81.2%)		5 (55.6%)	1 (33.3%)		1 (50%)	0 (0%)	
Sex	Female	13 (56.5%)	4 (25%)	0.099*	2 (22.2%)	2 (66.7%)	0.236*	1 (50%)	2 (66.7%)	1*
	Male	10 (43.5%)	12 (75%)		7 (77.8%)	1 (33.3%)		1 (50%)	1 (33.3%)	

* = Fisher

= Chi-square

Table 3. Association between clinicopathological characteristics and 1-year survival in wild-type gene subgroups

Characteristics		KRAS-Wild			NRAS-Wild			BRAF-Wild		
		Alive (n=30)	Death (n=14)	P	Alive (n=44)	Death (n=27)	P	Alive (n=51)	Death (n=27)	P
Primary tumor location	Left	20 (66.7%)	11 (78.6%)	0.809*	28 (63.6%)	23 (85.2%)	0.125*	34 (66.7%)	23 (85.2%)	0.222*
	Right	9 (30%)	3 (21.4%)		13 (29.5%)	3 (11.1%)		13 (25.5%)	3 (11.1%)	
	Unspecified	1 (3.3%)	0 (0%)		3 (6.8%)	1 (3.7%)		4 (7.8%)	1 (3.7%)	
Liver metastasis	No	5 (16.7%)	1 (7.1%)	0.647*	9 (20.5%)	1 (3.7%)	0.077*	10 (19.6%)	1 (3.7%)	0.086*
	Yes	25 (83.3%)	13 (92.9%)		35 (79.5%)	26 (96.3%)		41 (80.4%)	26 (96.3%)	
Lung metastasis	No	24 (80%)	12 (85.7%)	1*	34 (77.3%)	19 (70.4%)	0.516#	37 (72.5%)	20 (74.1%)	0.885#
	Yes	6 (20%)	2 (14.3%)		10 (22.7%)	8 (29.6%)		14 (27.5%)	7 (25.9%)	
Bone metastasis	No	28 (93.3%)	14 (100%)	1*	42 (95.5%)	26 (96.3%)	1*	49 (96.1%)	26 (96.3%)	1*
	Yes	2 (6.7%)	0 (0%)		2 (4.5%)	1 (3.7%)		2 (3.9%)	1 (3.7%)	
Lymph nodes metastasis	No	28 (93.3%)	13 (92.9%)	1*	40 (90.9%)	26 (96.3%)	0.643*	47 (92.2%)	26 (96.3%)	0.654*
	Yes	2 (6.7%)	1 (7.1%)		4 (9.1%)	1 (3.7%)		4 (7.8%)	1 (3.7%)	
Peritoneal metastasis	No	26 (86.7%)	10 (71.4%)	0.242*	40 (90.9%)	23 (85.2%)	0.468*	45 (88.2%)	23 (85.2%)	0.731*
	Yes	4 (13.3%)	4 (28.6%)		4 (9.1%)	4 (14.8%)		6 (11.8%)	4 (14.8%)	
Age	<50	11 (36.7%)	6 (42.9%)	0.694#	13 (29.5%)	7 (25.9%)	0.742#	16 (31.4%)	6 (22.2%)	0.393#
	≥50	19 (63.3%)	8 (57.1%)		31 (70.5%)	20 (74.1%)		35 (68.6%)	21 (77.8%)	
Sex	Female	8 (26.7%)	5 (35.7%)	0.540#	19 (43.2%)	7 (25.9%)	0.143#	20 (39.2%)	7 (25.9%)	0.240#
	Male	22 (73.3%)	9 (64.3%)		25 (56.8%)	20 (74.1%)		31 (60.8%)	20 (74.1%)	

* = Fisher; # = Chi-square

Table 4. Clinicopathological factors associated with 1-year survival in all patients

Characteristics		Alive (n=53)	Death (n=30)	P
Primary tumor location	Left	35 (66%)	25 (83.3%)	0.209*
	Right	14 (26.4%)	3 (10%)	
	Unspecified	4 (7.6%)	2 (6.7%)	
Liver metastasis	No	11 (20.8%)	1(3.3%)	0.048*
	Yes	42 (79.2%)	29 (96.7%)	
Lung metastasis	No	39 (73.6%)	22 (73.3%)	0.980#
	Yes	14 (26.4%)	8 (26.7%)	
Bone metastasis	No	51 (96.2%)	29 (96.7%)	1*
	Yes	2 (3.8%)	1(3.3%)	
Lymph nodes metastasis	No	48 (90.6%)	29 (96.7%)	0.410*
	Yes	5 (9.4%)	1(3.3%)	
Peritoneal metastasis	No	47 (88.7%)	26 (86.7%)	1*
	Yes	6 (11.3%)	4 (13.3%)	
Age	<50	17 (32.1%)	9 (30%)	0.845#
	≥50	36 (67.9%)	21 (70%)	
Sex	Female	21 (39.6%)	9 (30%)	0.381#
	Male	32 (60.4%)	21 (70%)	

* = Fisher; # = Chi-square

Bold numbers indicate statistically significant p-values ($P < 0.05$).

Table 5 presents the results of the multivariate logistic regression analysis for factors associated with 1-year survival. None of the evaluated variables showed a statistically significant association with 1-year survival (all $P > 0.05$).

Discussion

The purpose of this study was to determine the frequency

Table 5. Multivariate analysis of factors associated with 1-year survival

Variables		OR*	P
Sex	Female vs Male	1.39 (0.44-4.60)	0.579
KRAS	Mutant vs Wild	0.47 (0.14-1.45)	0.192
NRAS	Mutant vs Wild	2.59 (0.57-15.95)	0.250
BRAF	Mutant vs Wild	0.20 (0.01-2.22)	0.202
Primary tumor location	Right vs Left	2.90 (0.67-16.42)	0.179
Primary tumor location	Unspecified vs Left	0.71 (0.06-9.89)	0.780
Liver metastasis	Yes vs No	0.18 (0.01-1.41)	0.157
Lung metastasis	Yes vs No	1.21 (0.36-4.21)	0.757
Bone metastasis	Yes vs No	1.26 (0.07-44.43)	0.879
Lymph nodes metastasis	Yes vs No	1.80 (0.16-44.54)	0.658
Peritoneal metastases	Yes vs No	0.33 (0.05-1.98)	0.229
Age	≥ 50 vs < 50	0.72 (0.11-4.53)	0.727

* = Binary logistic regression

of KRAS, NRAS, and BRAF mutations in patients with mCRC and to evaluate their association with clinicopathological characteristics and 1-year survival. In this study, we found that KRAS mutations were the most frequently observed among the examined oncogenes, while NRAS and BRAF mutations were less common. Based on our analysis, the left-sided colon was the predominant primary tumor site across all mutation types, and the liver was the most frequent site of metastasis. We did not find significant associations between mutation status or clinicopathological features and 1-year survival, except for liver metastasis, which was linked to survival in the overall population.

The relatively high prevalence of KRAS mutations in our cohort may have important therapeutic implications,

as RAS-mutant tumors are resistant to anti-EGFR monoclonal antibodies.¹² It may therefore require alternative targeted treatment strategies. Furthermore, evidence indicates that the mutational landscape of colorectal cancer varies across racial, ethnic, and geographic populations.^{13, 14} This fact highlights the importance of region-based molecular epidemiology when interpreting mutation frequencies and developing precision oncology strategies.

The mutation rates for the K-RAS, N-RAS, and BRAF genes were 47%, 14.5%, and 6%, respectively, according to this study. These rates are comparable to those reported in other studies, such as the 33% K-RAS mutation rate in the study by Trevisiol and colleagues in Italy and the 21.6% K-RAS mutation rate in the study by Mikami and co-workers in Japan.^{15, 16} Variation across study populations and larger sample sizes in those studies may be the cause of these discrepancies. For instance, the mutation rates were 53% and 39.3% in studies conducted by Ryan et al. and Neumann et al, respectively.^{17, 18} Furthermore, Ahmadi and colleagues conducted a study in Iran that revealed a K-RAS mutation rate of 52%, which is comparable to the frequency reported in the current study (47%).¹⁹ Similar research populations could help explain this resemblance.

Similar to Dogan and others, most patients with KRAS mutation in our study had left-sided tumors; however, unlike their findings, we did not observe a statistically significant association between tumor location and 1-year survival.²⁰ Regarding liver metastasis, both studies reported no significant association with survival in univariate or multivariate analyses, indicating a consistent pattern between studies. These similarities and differences may be attributed to variations in patient selection, as Dogan and others exclusively included KRAS-mutant metastatic cases. In contrast, our study comprised both KRAS-mutant and wild-type patients.

The N-RAS mutation rate in Ahmadi et al.'s study was 4%, which is lower than the rate observed in the present study (14%). This difference may be caused by differences in laboratory techniques and detection methods, as variations in sequencing technologies can affect the sensitivity for identifying mutations.¹⁹ Additionally, in the study by Eshraghi and others, approximately 14.8% of the studied population had N-RAS mutations.²¹ The mutation rate in our study was 14.5%, which is comparable to that reported by Eshraghi and colleagues.

Ros and co-workers found BRAF mutations in 12% of patients with metastatic colorectal cancer. They found that a BRAF mutation was associated with a worse prognosis.²² Although the frequency of this oncogene was lower (6%) in the current study's general population, it was higher among deceased patients. However, this finding was not statistically significant, possibly because of differences in sample sizes between the two investigations. Although not statistically significant, the higher frequency of BRAF mutations among deceased patients may indicate a clinically relevant trend. BRAF-mutant colorectal cancer is characterized by aggressive tumor biology, increased

metastatic potential, and inferior survival outcomes.^{23, 24} Therefore, the absence of statistical significance in our study may reflect limited statistical power rather than the absence of a biological effect.

A statistically significant difference in BRAF gene mutation was observed by age, with a higher percentage of patients under 50 years old exhibiting this mutation ($P=0.032$). However, no substantial association with sex was identified. On the other hand, a study by D. Booker and colleagues found an association between the frequency of this mutation and sex, with a higher frequency in females.²⁵ Differences in methodology across studies, such as variations in diagnostic techniques or criteria for identifying the BRAF mutation, may account for this discrepancy.

In our study, the majority of BRAF-mutant patients were younger than 50 years, which aligns with findings from Soto et al, who reported a higher frequency of BRAF mutations among patients under 65 years.²⁶ However, in the COALA study from Australia, a higher proportion of BRAF mutations was observed in older patients, suggesting that the age distribution of BRAF-mutant colorectal cancer may vary across populations.²⁷

An important finding of the present study was the association between liver metastasis and 1-year survival. The liver is the most common site of metastatic spread in CRC and remains a major determinant of prognosis because hepatic tumor burden directly affects treatment eligibility and overall disease progression. Our findings suggest that anatomical disease extent may exert a substantial influence on short-term survival, potentially exceeding that of individual molecular alterations in certain clinical settings.²⁸⁻³⁰

This study revealed no significant association between mutations in the genes under investigation and 1-year patient survival. The findings of this study align with the research results obtained by Ahmadi et al. regarding the K-RAS and N-RAS genes.¹⁹ However, the study conducted by D. Booker et al. revealed an association between the frequency of BRAF mutations and reduced overall patient survival.²⁵ The observed differences in findings may be explained by variations in sample size and a longer follow-up period. These findings suggest that while these specific genetic alterations may not strictly dictate short-term (1-year) survival, their implications for long-term prognosis require further longitudinal investigation.

Limitations

The retrospective design, single-center setting, and relatively small sample size, particularly for NRAS and BRAF mutations, reduce statistical power and may limit generalizability. The follow-up period was limited to 1 year. Some clinical data, including detailed treatment regimens and comorbidities, were incomplete. Larger studies with larger sample sizes and more extended follow-up periods in the Iranian population are needed to validate these findings.

Despite these limitations, this study has potential

implications for identifying prognostic factors, particularly genetic alterations that may influence overall survival. Detecting these mutations could improve clinical planning and the personalized management of patients with mCRC.

Conclusion

This study found a significant association between BRAF mutations and an age of less than 50 years in patients with mCRC. However, no statistically significant associations were observed between BRAF mutations and other demographic factors or 1-year survival. Similarly, no significant associations were found between K-RAS and N-RAS mutations and demographic factors or 1-year survival. Despite the study's limitations, these findings contribute to the understanding of the molecular epidemiology of mCRC in the region and may support future development of personalized targeted therapies.

Authors' Contribution

Conceptualization: Abbas Eshraghi, Mohammad Sadegh Ghasemi, Jamshid Vafaeimanesh

Data curation: Mohammad Sadegh Ghasemi, Mohammad Sina Mirjani, Mohammad Reza Ahmadi

Formal analysis: Mohammad Sina Mirjani, Mostafa Vahedian

Funding acquisition: Abbas Eshraghi

Investigation: Abbas Eshraghi, Mohammad Sina Mirjan, Mohammad Reza Ahmadi

Methodology: Abbas Eshraghi, Mostafa Vahedian, Jamshid Vafaeimanesh

Project administration: Abbas Eshraghi

Resources: Abbas Eshraghi, Mohammad Sadegh Ghasemi

Software: Mohammad Sina Mirjani, Mostafa Vahedian

Supervision: Abbas Eshraghi, Jamshid Vafaeimanesh

Validation: Mostafa Vahedian, Mohammad Sadegh Ghasemi

Visualization: Mohammad Sina Mirjani, Mostafa Vahedian

Writing—original draft: Mohammad Sina Mirjani, Mohammad Reza Ahmadi

Writing—review & editing: Abbas Eshraghi, Jamshid Vafaeimanesh, Mostafa Vahedian, Mohammad Sadegh Ghasemi

Competing Interests

The authors declare no conflict of interest related to this work.

Ethical Approval

This study was approved by the Research Ethics Committee of Qom University of Medical Sciences (Approval ID: IR.MUQ.REC.1401.207, Approval Date: January 8, 2023).

Funding

This study was conducted as part of the Internal Medicine residency thesis of Dr. Mohammad Sadegh Ghasemi and was financially supported by the Vice-Presidency for Research and Technology of Qom University of Medical Sciences.

References

- Mattiuzzi C, Sanchis-Gomar F, Lippi G. Concise update on colorectal cancer epidemiology. *Ann Transl Med* 2019;7(21):609. doi:10.21037/atm.2019.07.91
- Lopes SR, Martins C, Santos IC, Teixeira M, Gamito É, Alves AL. Colorectal cancer screening: a review of current knowledge and progress in research. *World J Gastrointest Oncol* 2024;16(4):1119-33. doi:10.4251/wjgo.v16.i4.1119
- Monahan BV, Patel T, Poggio JL. Stage IV colorectal cancer at initial presentation versus progression during and after treatment, differences in management: management differences for initial presentation versus progression of disease after initial treatment. *Clin Colon Rectal Surg* 2024;37(2):108-13. doi:10.1055/s-0043-1761626
- Hamers P, Bos AC, May AM, Punt CJ, Koopman M, Vink GR. Recent changes in overall survival of real-life stage IV colorectal cancer patients. *J Clin Oncol* 2019;37(15 Suppl):3522. doi:10.1200/JCO.2019.37.15_suppl.3522
- Vemala RN, Katti SV, Sirohi B, Manikandan D, Nandakumar G. Molecular oncology in management of colorectal cancer. *Indian J Surg Oncol* 2021;12(Suppl 1):169-80. doi:10.1007/s13193-021-01289-6
- Armaghany T, Wilson JD, Chu Q, Mills G. Genetic alterations in colorectal cancer. *Gastrointest Cancer Res* 2012;5(1):19-27.
- Prior IA, Lewis PD, Mattos C. A comprehensive survey of Ras mutations in cancer. *Cancer Res* 2012;72(10):2457-67. doi:10.1158/0008-5472.Can-11-2612
- Yaeger R, Cercek A, Chou JF, Sylvester BE, Kemeny NE, Hechtman JF, et al. BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer. *Cancer* 2014;120(15):2316-24. doi:10.1002/cncr.28729
- Benmokhtar S, Laraqui A, Hilali F, Bajjou T, El Zaitouni S, Jafari M, et al. RAS/RAF/MAPK pathway mutations as predictive biomarkers in Middle Eastern colorectal cancer: a systematic review. *Clin Med Insights Oncol* 2024;18:11795549241255651. doi:10.1177/11795549241255651
- Karagkounis G, Torbenson MS, Daniel HD, Azad NS, Diaz LA Jr, Donehower RC, et al. Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases. *Cancer* 2013;119(23):4137-44. doi:10.1002/cncr.28347
- Afrăsănie VA, Marinca MV, Alexa-Stratulat T, Gafton B, Păduraru M, Adavidoaiei AM, et al. KRAS, NRAS, BRAF, HER2 and microsatellite instability in metastatic colorectal cancer - practical implications for the clinician. *Radiol Oncol* 2019;53(3):265-74. doi:10.2478/raon-2019-0033
- Grochot R, Bartolini M, Algaze S, Reimann P, Winder T, Lenz HJ, et al. Emerging and established targets in colorectal cancer: translating biology into therapeutics. *Am Soc Clin Oncol Educ Book* 2026;46(3): e516576. doi:10.1200/edbk-26-516576
- Rodriguez GM, Aljehani M, DePuy D, Patel SR, Fisher GA Jr, Lin AY. KRAS variant frequency and colorectal cancer-specific survival by race and ethnicity. *JAMA Netw Open* 2026;9(3): e261585. doi:10.1001/jamanetworkopen.2026.1585
- Kassaw AB, Abera MB, Seid MA, Jemal M, Ahmed H, Asfaw MS, et al. KRAS mutation and its association with clinicopathological features of colorectal cancer patients in Africa: a systematic review and meta-analysis. *BMC Cancer* 2026;26(1):31. doi:10.1186/s12885-025-15356-6
- Mikami M, Noshio K, Yamamoto H, Takahashi T, Maehata T, Taniguchi H, et al. Mutational analysis of beta-catenin and the RAS-RAF signalling pathway in early flat-type colorectal tumours. *Eur J Cancer* 2006;42(17):3065-72. doi:10.1016/j.ejca.2006.06.029
- Travisoli C, Di Fabio F, Nascimbeni R, Peloso L, Salbe C, Ferruzzi E, et al. Prognostic value of circulating KRAS2 gene mutations in colorectal cancer with distant metastases. *Int J Biol Markers* 2006;21(4):223-8. doi:10.5301/ijbm.2008.3336
- Ryan BM, Lefort F, McManus R, Daly J, Keeling PW, Weir DG, et al. A prospective study of circulating mutant KRAS2 in the serum of patients with colorectal neoplasia: strong prognostic indicator in postoperative follow up. *Gut* 2003;52(1):101-8. doi:10.1136/gut.52.1.101
- Neumann J, Zeindl-Eberhart E, Kirchner T, Jung A. Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. *Pathol Res Pract* 2009;205(12):858-62. doi:10.1016/j.prp.2009.07.010

19. Shahriari-Ahmadi A, Ansarinejad N, Fardad F, Abbaszadeh M, Sadeghi M. KRAS and NRAS testing in metastatic colorectal cancer in Central Iran (Tehran): a review on literature of the middle east. *Indian J Med Paediatr Oncol* 2018;39(02):210-4. doi:[10.4103/ijmpo.ijmpo_133_17](https://doi.org/10.4103/ijmpo.ijmpo_133_17)
20. Dogan E, Cengiz M, Bozkurt O, Inanc M, Ozkan M. Impact of clinicopathological features on prognosis in KRAS mutant metastatic colorectal cancer. *Uluslar Hematol Onkol Derg* 2025;35(1):12-6. doi:[10.4999/uhod.257981](https://doi.org/10.4999/uhod.257981)
21. Eshraghi A, Esfandbod M, Safaei Nodehi SR, Shahi F, Eshraghi A. The predictive value of KRAS and NRAS mutations in metastatic colorectal cancer. *Med J Islam Repub Iran* 2020;34:39. doi:[10.34171/mjiri.34.39](https://doi.org/10.34171/mjiri.34.39)
22. Ros J, Rodríguez-Castells M, Saoudi N, Baraibar I, Salva F, Tabernero J, et al. Treatment of BRAF-V600E mutant metastatic colorectal cancer: new insights and biomarkers. *Expert Rev Anticancer Ther* 2023;23(8):797-806. doi:[10.1080/14737140.2023.2236794](https://doi.org/10.1080/14737140.2023.2236794)
23. Oyelami M, Mgbekpe O, Obadijah AA, Egbeyemi A, Marshall E. The prognostic significance of KRAS, NRAS, and BRAF mutations in colorectal cancer: a systematic review and meta-analysis. *Clin Med Insights Oncol* 2026;20:11795549261417367. doi:[10.1177/11795549261417367](https://doi.org/10.1177/11795549261417367)
24. Napolitano S, Ciardiello D, Cioli E, Martinelli E, Troiani T, Giulia Zampino M, et al. BRAFV600E mutant metastatic colorectal cancer: current advances in personalized treatment and future perspectives. *Cancer Treat Rev* 2025;134:102905. doi:[10.1016/j.ctrv.2025.102905](https://doi.org/10.1016/j.ctrv.2025.102905)
25. Booker BD, Markt SC, Schumacher FR, Rose J, Cooper G, Selfridge JE, et al. Variation in KRAS/NRAS/BRAF-mutation status by age, sex, and race/ethnicity among a large cohort of patients with metastatic colorectal cancer (mCRC). *J Gastrointest Cancer* 2024;55(1):237-46. doi:[10.1007/s12029-023-00954-z](https://doi.org/10.1007/s12029-023-00954-z)
26. Soto J, Bringas M, Alonso NG, Martín AJ, Ferrándiz AC, Pérez-Solero GT, et al. Clinical and survival characteristics of patients with BRAF-mutated metastatic colorectal cancer (mCRC) who receive metastases surgery in a Spanish cohort. *J Clin Oncol* 2023;41(4 Suppl):66. doi:[10.1200/JCO.2023.41.4_suppl.66](https://doi.org/10.1200/JCO.2023.41.4_suppl.66)
27. Hitchen N, Wong HL, Wong R, Shapiro J, Burge M, Nott L, et al. Real-world characteristics and outcomes of patients with BRAF(V600E)-mutant metastatic colorectal cancer in Australia: the COALA project. *ESMO Real World Data Digit Oncol* 2025;9:100178. doi:[10.1016/j.esmorw.2025.100178](https://doi.org/10.1016/j.esmorw.2025.100178)
28. Ma Q, Liu F, Lv X. Prognostic impact of tumour burden score on colorectal cancer liver metastasis survival following resection: a meta-analysis. *Clin Transl Oncol* 2026. doi:[10.1007/s12094-026-04459-6](https://doi.org/10.1007/s12094-026-04459-6)
29. Cavallaro P, Bordeianou L, Stafford C, Clark J, Berger D, Cusack J, et al. Impact of single-organ metastasis to the liver or lung and genetic mutation status on prognosis in stage IV colorectal cancer. *Clin Colorectal Cancer* 2020;19(1): e8-17. doi:[10.1016/j.clcc.2019.12.001](https://doi.org/10.1016/j.clcc.2019.12.001)
30. Kow AW. Hepatic metastasis from colorectal cancer. *J Gastrointest Oncol* 2019;10(6):1274-98. doi:[10.21037/jgo.2019.08.06](https://doi.org/10.21037/jgo.2019.08.06)